Skip to Main Content

Paper Details

Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval.
Oncotarget
0
2019
Author NameAffiliation
Joan AlbanellHospital del Mar, Universitat Pompeu Fabra
  • 1 - 1

Datasets

Release 1.2